Immunohistochemical and Histopathological Study of Anaplastic Lymphoma Kinase and Tyrosine-kinase Receptor Expression in Bronchogenic Carcinoma
DOI:
https://doi.org/10.3889/oamjms.2021.5671Keywords:
Anaplastic Lymphoma Kinase Expression, Tyrosine-kinase Receptor Expression, Lung CarcinomaAbstract
BACKGROUND: Adenocarcinoma of the lung is the most common tumor type of primary lung cancer and is characterized by heterogeneity on the molecular, clinical, and pathological levels. The presence of an anaplastic lymphoma kinase (ALK) fusion oncogene defines a molecular subset of non-small cell lung cancer with distinct clinical and pathologic features. Furthermore, the tyrosine-kinase receptor (C-kit) is considered to be expressed in various solid tumors, including carcinomas of the lung.
AIM: This study aims to correlate immunohistochemical (IHC) expression of ALK and C-kit with pathological features of lung carcinoma and to correlate IHC expression of ALK with IHC expression of C-kit in lung carcinoma.
MATERIALS AND METHODS: The material of this study consists of paraffin blocks of 60 cases of patients with bronchogenic carcinoma, IHC staining with ALK and C-kit then analysis of immunoreactivity scoring was done.
RESULTS: As regards ALK expression, 3 (5%) cases showed positive expression of ALK and 57 (95%) cases showed negative expression of ALK with no statistically significant correlation between the ALK expression and the histopathological type. While C-kit expression, 4 (6.7%) cases showed positive expression and 56 (93.3%) cases showed negative expression of C-kit with statistically significant correlation between the C-kit expression and the histopathological type.
CONCLUSION: There is an association between expression of c-kit and tumor histological type in lung carcinoma. Expression was notably significant among adenocarcinomas and small cell carcinomas.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Devesa, SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type; male: Female differences diminishing and adenoca1cinoma rates rising. Int J Cancer. 2005;117(2):294-9. https://doi.org/10.1002/ijc.21183 PMid:15900604
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-8. PMid:17982442
Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508-15. https://doi.org/10.1038/modpathol.2009.2 PMid:19234440
McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymhoma kinase inhibitors. Cancer Res. 2008;68(9):3389-95. https://doi.org/10.1158/0008-5472.can-07-6186 PMid:18451166
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703. https://doi.org/10.1517/14728222.2011.550880 PMid:20979469
Le Quesne J, Maurya M, Yancheva SG, O’Brien M, Popat S, Wotherspoon AC, et al. A comparison of immunohistochemical assays and FISH in detecting the Alk translocation in diagnotic histological and cytological lung tumor material. J Thorac Oncol. 2014;9(6):769-74. https://doi.org/10.1097/jto.0000000000000157 PMid:24787965
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res. 2009;15(16):5216-23. https://doi.org/10.1158/1078-0432.ccr-09-0802 PMid:19671850
Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of Alk-rearranged lung adenocarcinoma based on driver oncogene mutations: Frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One. 2013;8(10):e76999. https://doi.org/10.1371/journal.pone.0076999 PMid:24194854
LaPoint RJ, Bourne PA, Wang HL, Xu H. Co expression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. Appl Immunohistochem Mol Morphol. 2007;15(4):401-6. https://doi.org/10.1097/01.pai.0000213153.41440.7d PMid:18091382
Mojica WD, Saena R, Starostik P, Cheney RT. CD117+ small cell lung cancer lacks the asp 816--val point mutation in exon 17. Histopathology. 2005;47(5):517-22. https://doi.org/10.1111/j.1365-2559.2005.02259.x PMid:16242000
Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumor. Pathol Int. 2006;56(1):1-9. PMid:16398673
Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in sclc cell lines and xenografts. Brit J Cancer. 1993;67(1):37-46. https://doi.org/10.1038/bjc.1993.7 PMid:7678980
Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, et al. Preferential localisation of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424(2):135-41. https://doi.org/10.1007/bf00193492 PMid:7514077
Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6(3):459-65. https://doi.org/10.1097/jto.0b013e318209edb9 PMid:21278610
Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr., Morton RF, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: A CALGB and NCCTG study. Ann Oncol. 2005;16(11):1811-6. https://doi.org/10.1093/annonc/mdi365 PMid:16087693
Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS One. 2013;8(5):e64821. https://doi.org/10.1371/journal.pone.0064821 PMid:23741400
Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9(3):295-306. https://doi.org/10.1097/jto.0000000000000072 PMid:24518086
Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One. 2013;8(1):e52261. https://doi.org/10.1371/journal.pone.0052261 PMid:23359795
Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77(2):288-92. https://doi.org/10.1016/j.lungcan.2012.03.004 PMid:22465695
Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466-72. https://doi.org/10.1097/jto.0b013e31820b82e8 PMid:21258247
Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: Implications for optimal clinical testing. Arch Pathol Lab Med. 2012;136(7):796-803. https://doi.org/10.5858/arpa.2011-0321-oa PMid:22742552
Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: Comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med. 2014;138(11):1449-58. https://doi.org/10.5858/arpa.2013-0388-oa PMid:24885803
Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8(1):45-51. https://doi.org/10.1097/jto.0b013e318274a83e PMid:23196275
Selinger CI, Rogers TM, Russell PA, O’Toole S, Yip P, Wright GM, et al. Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26(12):1545-53. https://doi.org/10.1038/modpathol.2013.87 PMid:23743928
To KF, Tong JH, Yeung KS, Lung RW, Law PP, Chau SL, et al. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4- ALK variant. J Thorac Oncol. 2013;8(7):883-91. https://doi.org/10.1097/jto.0b013e3182904e22 PMid:23625156
Zhou J, Zhao J, Sun K, Wang B, Wang L, Chen X, et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. PLoS One. 2014;9(3):e92828. https://doi.org/10.1371/journal.pone.0092828 PMid:24667320
Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152-8. https://doi.org/10.1016/j.humpath.2009.01.012 PMid:19386350
Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143-9. https://doi.org/10.1158/1078-0432.ccr-08-3248 PMid:19383809
Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010;63(12):1066-70. https://doi.org/10.1136/jcp.2010.081166 PMid:20935334
Sakai Y, Nakai T, Ohbayashi C, Imagawa N, Yanagita E, Satake R, et al. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. Int J Surg Pathol. 2013;21(5):476-82. https://doi.org/10.1177/1066896913489345 PMid:23794492
Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10):2589-93. https://doi.org/10.1093/annonc/ mdt295 PMid:23904459
Han XH, Zhang NN, Ma L, Lin DM, Hao XZ, Liu YT, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. 2013;463(4):583-91. https://doi.org/10.1007/s00428-013-1472-7 PMid:23955278
Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu G, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;9(7):e101551. https://doi.org/10.1371/journal.pone.0101551 PMid:24992725
McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol. 2012;7(2):348-54. https://doi.org/10.1097/jto.0b013e3182381535 PMid:22071784
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-44. https://doi.org/10.1200/jco.2005.04.4859 PMid:17008692
Xuan H, Jingshu G, Fang Y, Na L, Xiaolin S, Zhaoyang Y, et al. Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China. Histol Histopathol. 2014;29(2):273-8. PMid:23965952
Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol. 2002;33(12):1182-7. https://doi.org/10.1053/hupa.2002.129199 PMid:12514786
Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer. 2003;39(6):793-9. https://doi.org/10.1016/s0959-8049(03)00026-1 PMid:12651205
Micke P, Basrai M, Faldum A, Bittinger F, Rönnstrand L, Blaukat A, et al. Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications. Clin Cancer Res. 2003;9(1):188-94. PMid:12538468
Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol. 2003;16(10):1041-7. https://doi.org/10.1097/01.mp.0000089780.30006.de PMid:14559988
Rohr UP, Rehfeld N, Pflugfelder L, Geddert H, Müller W, Steidl U, et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer. 2004;111(2):259-63. https://doi.org/10.1002/ijc.20252 PMid:15197780
Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, et al. Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer. 2006;52(3):343-7. https://doi.org/10.1016/j. lungcan.2006.02.003
PMid:16574270
López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, et al. Prognostic value of KIT expression in small cell lung cancer. Lung Cancer. 2007;56(3):405-13. https://doi.org/10.1016/j.lungcan.2007.01.029
PMid:17420067
Downloads
Published
How to Cite
License
Copyright (c) 2021 Ahmed Fawzy, Samira Mahmoud Abd Allah, Mostafa Mohammed Salem, Lobna Omar Al Farouk (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
